The zinc-and calcium-dependent family of proteins called the MMPs (matrix metalloproteases) are collectively responsible for the degradation of the extracellular matrix. The enzymes are synthesized as zymogens, and under physiological conditions are selectively regulated by endogenous inhibitors. An imbalance between the active enzymes and their natural inhibitors leads to the accelerated destruction of connective tissue associated with the pathology of diseases such as arthritis, cancer, multiple sclerosis and cardiovascular diseases. The potential for using specific enzyme inhibitors as therapeutic agents to redress this balance has led to intensive research focused on the design, synthesis and molecular deciphering of low-molecular-mass inhibitors of this family of proteins. The design of early MMP inhibitors was based on the scissile site sequence of peptide substrates, with moieties customized to chelate the critical zinc ion at the enzymes' active site. These initial efforts were supported by X-ray and NMR data on MMP complexes, exploiting sequence and structural differences in the principal specificity pocket of the enzymes, leading to subtype-selective MMP inhibitors. This review will provide a critical appraisal of the design principles that have been utilized in generating molecules that inhibit MMPs, and explore issues relevant to obtaining clinical efficacy of MMP inhibitor-based therapies.
Introduction
The extracellular matrix cascade [1] , which includes the MMPs (matrix metalloproteases), is involved in events such as embryogenesis, wound healing and metastasis, to name but a few [2, 3] . MMPs are a zinc-and calcium-dependent family of proteins that are collectively responsible for the degradation of the extracellular matrix [4] . The enzymes are synthesized as zymogens [5] , and under physiological conditions are selectively regulated by endogenous inhibitors. An imbalance between the active enzymes and their natural inhibitors leads to the accelerated destruction of connective tissue, which is associated with the pathology of diseases such as arthritis, cancer, multiple sclerosis and cardiovascular diseases [6] [7] [8] [9] [10] . The potential for using specific enzyme inhibitors as therapeutic agents to redress this balance has led to intensive research [11] [12] [13] focused on the design, synthesis and molecular deciphering of low-molecular-mass inhibitors of this family of proteins.
Design of early MMP inhibitors
Cartilage is a complex connective tissue composed of collagen and proteoglycan [14] [15] [16] [17] . Collagen, which gives connective tissue its strength and rigidity, is normally resistant to proteases due to its unique supercoiled triple helix structure. However, collagenase (MMP-1) is the only protease capable Key words: crystallography, inhibitor, matrix metalloprotease (MMP), optimization, selectivity, structure. Abbreviation used: MMP, matrix metalloprotease. of effecting cleavage of the three-stranded collagen at a single point across the three protein chains, producing threequarter and one-quarter fragments of the native molecule [18] . The cleaved products then denature spontaneously and become susceptible to other proteases, resulting ultimately in the complete degradation of fibrillar collagen. This leads to joint swelling and joint degradation, and culminates in the symptoms of osteoarthritis and rheumatoid arthritis [4, 19, 20] . The initial cleavage of collagen by collagenase is the critical irreversible step leading to the abnormalities observed in the disease state. Work carried out at Roche UK was aimed at providing a cure for rheumatoid arthritis, by focusing on blocking the cleavage of type II collagen by fibroblast collagenase (MMP-1) through the design of effective, orally available, low-molecular-mass MMP-1 inhibitors [11] .
The primary structures of the collagenases show that the proteins are similar and modular, each possessing a signal peptide of 20 residues, a propeptide domain (80 amino acids) conferring latency, a zinc-containing catalytic domain of approx. 180 residues, and a substrate specificity domain (210 amino acids) [21] [22] [23] . The three-dimensional scaffold of the catalytic domain is composed of a five-stranded β-sheet and three α-helices (Figure 1 ), similar to the β-sandwich architecture observed in zinc-dependent endopeptidases [24] of this superfamily. A deep cleft around the catalytic zinc located towards the C-terminus of the domain delineates the active site and substrate-binding region of the protease. Three histidine residues of the protein and atoms of the bound inhibitor chelate the catalytic zinc. Additionally, there is a second, structural zinc and several calcium atoms that stabilize the structure. 
Warhead
Hydroxamate was found to be the preferred chelator for the preparation of collagenase inhibitors. In the case of MMPs, the hydroxamate moiety offers two oxygen atoms to bind to the zinc as well as a nitrogen atom to the carbonyl of the backbone of the protein, and results in compounds with nanomolar affinity. In contrast, other potential chelators, such as thiols, phosphinic acid and carboxylic acid, all result in a fall in potency. Moreover, as corroborated by modelling studies, insertion of a one-carbon spacer group between the zinc ligand and the α centre of the P1 residue (Figure 2 ) is optimal in order to achieve highest potency.
Residue requirements
Early structure-activity relationship studies [25] showed that the subsites that recognize the residues N-terminal to the scissile bond are flat and ill-defined, so that compounds spanning unprimed subsites result in inhibitors with micromolar potency. Thus subsequent medicinal chemistry and structural biology efforts have been concentrated on probing enzyme-inhibitor interactions of analogues straddling the S1 -S3 subsites [26] .
As highlighted in Figure 2 , the P1 residue (Leu in the inhibitor shown) binds to a deep lipophilic pocket in the enzyme. The P2 side chain is oriented away from the enzyme, allowing the positioning of large moieties in this location without detriment to the potency of the inhibitor. The P3 residue, located at the edge of the catalytic domain, will only tolerate small residues. Interestingly, both the P1 -P2 and the P2 -P3 backbone amide functionalities are required for binding. These features were exploited through the use of traditional medicinal chemistry in partnership with X-ray crystallography and modelling.
Refining the model
Although early inhibitors were potent in the nanomolar range, their strong peptidic nature resulted in less than ideal pharmacokinetic properties (chemical and metabolic stability, solubility, permeability). A number of cyclized analogues aimed at improving bioavailability were prepared. Interestingly, crystallographic studies revealed that, despite the lack of the full repertoire of hydrogen bonds, these compounds of nanomolar potency occupied the same subsites as the extended inhibitors. This implies that the zinc chelator and the P1 residues are the dominant features guiding the inhibitor to the active site of the enzyme. Thus shorter inhibitors and inhibitors involved in less than favourable interactions, such as the lactams, can still interact with the enzyme.
Selectivity issues
Although the hydrophobic character of the S1 pocket is maintained in all MMPs, there is considerable variation in the amino acids defining the shape and size of this subsite in the individual MMPs [27] . These changes can be exploited in preparing synthetic inhibitors with preferences for individual MMPs. For example, a buried arginine residue (Arg 214 ) located at the start of the catalytic helix severely limits the size of the S1 pocket in fibroblast collagenase (MMP-1) (Figure 3 ). Thus the compact methyl cyclopentyl chain, a salient feature of the P1 position in Trocade, gives rise to a potent collagenase inhibitor that is less effective against stromelysin and gelatinase, which have an Arg 214 → Leu modification and therefore prefer long alkyl side chains at that position [26, 28, 29] . Similarly, an asparagine residue on β-sheet IV of the protein can interact favourably with a P1 (α) hydantoin moiety of the Trocade. The substitution of a valine and a leucine residue at the corresponding position in the structures of stromelysin and gelatinase respectively results in the loss of the P1 (α) interaction in these enzymes. Selectivity has thus been achieved by making use of inherent differences between amino acids that occupy equivalent locations in related enzymes. 
Biological results
Extensive early studies showed that Trocade is an orally available, potent, selective collagenase inhibitor that prevents cartilage resorption both in vitro and in vivo. Trocade prevents articular cartilage loss and bone changes in animal models of arthritis, making it a highly promising candidate for use with humans [30] .
Clinical results
In humans, Trocade was well tolerated at single oral doses, and the terminal elimination phase half-life supported a once-daily dosing regimen [30] . Trocade went into clinical trials designed to detect retardation in structural changes in rheumatoid arthritis. Despite the high expectations and its undeniable efficacy in animal models, the medical trials for Trocade, as with all first-generation clinical candidates targeting MMPs, were terminated prematurely due to unforeseen complications.
Conclusions
The reasons behind the disappointing results from the clinical trials of the first-generation MMP inhibitors are still being deliberated. With the escalating database of information on the biology of MMPs, it has become possible to endorse different advances towards blocking these enzymes. For instance, the use of MMP inhibitors, in combination therapy and in early stages of disease onset, could be a novel approach geared towards achieving improved clinical advantage. Nevertheless, the design of the first-generation MMP inhibitors has demonstrated that synergy between medical chemistry, structural biology and molecular modelling provides a persuasive means of accelerating the lead optimization process.
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